

Chris Jones

From: Mark Deming <MDeming@Polsinelli.com>
Sent: Tuesday, March 10, 2026 1:13 PM
To: Sitzman, Mike
Cc: Best, Timothy; Hurley, Hannah; Noorassa, Anisa; Shook, Allison; Tobin, David; Padagis DNS
Subject: RE: Neurelis v Padagis - Deposition Scheduling

Mike,

I also wanted to follow-up on the proposed deposition dates. We don't want to lose availability.

Thanks,
Mark

From: Mark Deming <MDeming@Polsinelli.com>
Sent: Tuesday, March 10, 2026 11:50 AM
To: Sitzman, Mike <msitzman@mcdermottlaw.com>
Cc: Best, Timothy <tbest@mcdermottlaw.com>; Hurley, Hannah <hhurley@mcdermottlaw.com>; Noorassa, Anisa <Anoorassa@mcdermottlaw.com>; Shook, Allison <ashook@mcdermottlaw.com>; Tobin, David <dtobin@mcdermottlaw.com>; Padagis DNS <padagis-dns@polsinelli.com>
Subject: RE: Neurelis v Padagis - Deposition Scheduling

Mike,

Padagis expects to make the certification and send the notice letter in the next week or so.

We're continuing to look into the correspondence question, but again if there's anything particular you can point us to it would help us focus our efforts.

Thank you,
Mark

Mark Deming

Shareholder

mdeming@polsinelli.com

312.873.3625

150 N. Riverside Plaza, Suite 3000
Chicago, IL 60606

Polsinelli PC, Polsinelli LLP in California

polsinelli.com

From: Mark Deming <MDeming@Polsinelli.com>
Sent: Friday, March 6, 2026 1:52 PM
To: Sitzman, Mike <msitzman@mcdermottlaw.com>
Cc: Best, Timothy <tbest@mcdermottlaw.com>; Hurley, Hannah <hhurley@mcdermottlaw.com>; Noorassa, Anisa <Anoorassa@mcdermottlaw.com>; Shook, Allison <ashook@mcdermottlaw.com>; Tobin, David <dtobin@mcdermottlaw.com>; Padagis DNS <padagis-dns@polsinelli.com>
Subject: RE: Neurelis v Padagis - Deposition Scheduling

Mike,

I don't have information about when Padagis might certify to the '400 patent, but I'll check with the client.

Regarding FDA correspondence, this is the first I recall hearing you think anything is missing. We will double check with the client, but if you have any particular reasons to think anything is missing please let us know what they are as they may help us track things down.

Thank you,
Mark

Mark Deming

Shareholder

mdeming@polsinelli.com

312.873.3625


150 N. Riverside Plaza, Suite 3000
Chicago, IL 60606

Polsinelli PC, Polsinelli LLP in California

polsinelli.com

From: Sitzman, Mike <msitzman@mcdermottlaw.com>
Sent: Thursday, March 5, 2026 4:54 PM
To: Mark Deming <MDeming@Polsinelli.com>
Cc: Best, Timothy <tbest@mcdermottlaw.com>; Hurley, Hannah <hhurley@mcdermottlaw.com>; Noorassa, Anisa <Anoorassa@mcdermottlaw.com>; Shook, Allison <ashook@mcdermottlaw.com>; Tobin, David <dtobin@mcdermottlaw.com>; Padagis DNS <padagis-dns@polsinelli.com>
Subject: RE: Neurelis v Padagis - Deposition Scheduling

EXTERNAL EMAIL msitzman@mcdermottlaw.com



Mark – thank you for your messages below. We are reviewing internally and will revert back. Two preliminary items:

1. When is Padagis going to certify as to the '400 Patent? We discussed this issue several weeks ago and we had expected to receive a PIV by now. Please update us as to when we can expect it.
2. We are still missing certain FDA correspondence between FDA and Padagis (including the individuals below). Will you review with Padagis to ensure that we have a complete set of correspondence.

Thanks,
Mike

Michael Sitzman
Partner

T: +1 628 218 3917 | M: +1 415 254 0654 | F: +1 628 218 3900
msitzman@mcdermottlaw.com | [LinkedIn](#)

McDermott Will & Schulte LLP | mcdermottlaw.com
415 Mission Street, Suite 5600 | San Francisco, CA 94105 | USA



From: Mark Deming <MDeming@Polsinelli.com>
Sent: Wednesday, March 4, 2026 8:11 AM
To: Sitzman, Mike <msitzman@mcdermottlaw.com>
Cc: Valtoco-MWE <Valtoco-MWE@mcdermottlaw.com>; Padagis DNS <padagis-dns@polsinelli.com>
Subject: RE: Neurelis v Padagis - Deposition Scheduling

[External Email]

Mike,

The third Israel witness is [REDACTED]. He is available March 18.

Thank you,
Mark

Mark Deming

Shareholder

mdeming@polsinelli.com

312.873.3625

150 N. Riverside Plaza, Suite 3000
Chicago, IL 60606

Polsinelli PC, Polsinelli LLP in California

polsinelli.com

From: Mark Deming <MDeming@Polsinelli.com>
Sent: Monday, March 2, 2026 3:32 PM

To: Sitzman, Mike <msitzman@mwe.com>

Cc: Valtoco-MWE <Valtoco-MWE@mwe.com>; Padagis DNS <padagis-dns@polsinelli.com>

Subject: Neurelis v Padagis - Deposition Scheduling

Mike,

With the fact deadline coming up, we wanted to get you our witnesses' availability for remote depositions.

- [REDACTED]: April 2-3 or 9
- [REDACTED]: March 31
- [REDACTED]: March 24-26

Please note that [REDACTED] and [REDACTED] are in Israel, and while we hope there won't be any disruptions with their availability, we appreciate your patience if adjustments are needed. There is a final witness, also located in Israel, for which we are confirming availability. For each of them, we propose the depositions begin at 2pm Israel time and conclude by 8pm Israel time. Please note that Israel's seasonal time does not change on the same schedule as the United States, so please take that into account when setting your local time.

We'd also appreciate you providing the availability for the witnesses you have designated or otherwise represent:

[REDACTED] (designee for topics 3, 5, 12); [REDACTED] (designee for topics 20-23, 25, 28-29); [REDACTED] (designee for topic 26); [REDACTED] (designee for topics 32, 34); Steve Cartt; Steve Medeiros; Garry Gwozdz; Mark Mitchnick; and David Hale.

In addition, we understand you are not representing [REDACTED], but you had been in touch with him on multiple occasions, and we had requested you share your contact information for him. Please provide that as soon as possible so we can reach out to him.

Finally, when we paused on depositions last summer, I don't believe we'd resolved the issue of topics for which Neurelis had not designated witnesses: 1, 2, 4, 6-11, 13-19, 24, 27, 30-31, 33, and 35-38. Please let us know if Neurelis will be designating witnesses for any of those topics, or if you're available to meet and confer otherwise.

Thank you,
Mark

Mark Deming

Shareholder

mdeming@polsinelli.com

312.873.3625

150 N. Riverside Plaza, Suite 3000
Chicago, IL 60606

Polsinelli PC, Polsinelli LLP in California

polsinelli.com

This electronic mail message contains CONFIDENTIAL information which is (a) ATTORNEY - CLIENT PRIVILEGED COMMUNICATION, WORK PRODUCT, PROPRIETARY IN NATURE, OR OTHERWISE PROTECTED BY LAW FROM DISCLOSURE, and (b) intended only for the use of the Addressee(s) named herein. If you are not an Addressee, or the

person responsible for delivering this to an Addressee, you are hereby notified that reading, copying, or distributing this message is prohibited. If you have received this electronic mail message in error, please reply to the sender and take the steps necessary to delete the message completely from your computer system.

This message is a PRIVATE communication. This message and all attachments are a private communication sent by a law firm and may be confidential or protected by privilege. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the information contained in or attached to this message is strictly prohibited. Please notify the sender of the delivery error by replying to this message, and then delete it from your system. Our [Privacy Policy](#) explains how we may use your personal information. Thank you.

Please visit <http://www.mwe.com/> for more information about our Firm.